This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 17.86% and 2.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
UpHealth, Inc. (UPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
UpHealth, Inc. (UPH) delivered earnings and revenue surprises of -28.57% and 2.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -62.50% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
XpresSpa Group, Inc. (XSPA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 33.33% and 23.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 25.95% and 3.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Assure Holdings Corp. (IONM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -50% and 8.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LifeMD, Inc. (LFMD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 25.64% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Will Interpace Diagnostics (IDXG) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Interpace Diagnostics (IDXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best ETFs & Stocks From the Top Sector of Q3
by Sweta Killa
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm
by Zacks Equity Research
The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.
LabCorp & Interpace Team Up, Drive Specialty Diagnostics
by Zacks Equity Research
Per the new deal with Interpace, Dianon Pathology, member of the LabCorp (LH) Specialty Testing Group, is supposed to perform the thyroid biopsy analysis.
LabCorp Completes $1.2-Billion Chiltern Buyout, Boosts CRO
by Zacks Equity Research
In line with its inorganic growth strategy, LabCorp's (LH) latest Chiltern buyout is aimed at promoting the CRO business.
6 Things to Know About Business Services Sector
by Zacks Equity Research
Stocks in the Business Services sector have been strong performers lately, with the sector in the S&P 500 up more than the index both in the year-to-date and trailing 12-month periods.